Allan Reine - Jan 17, 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Chief Financial Officer
Signature
/s/ Marishka DeToy, attorney-in-fact
Stock symbol
PRME
Transactions as of
Jan 17, 2024
Transactions value $
$0
Form type
4
Date filed
1/19/2024, 04:19 PM
Previous filing
Jan 17, 2024
Next filing
May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +600K $0.00 600K Jan 17, 2024 Common Stock 600K $6.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on January 17, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.